FDA approves marketing of BioFire COVID-19 test

Mar 17, 2021

2020 07 16 23 29 1615 Laboratory Scientist Biosafety 400

The U.S. Food and Drug Administration (FDA) announced it has granted marketing approval for the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs obtained from individuals suspected of COVID-19 and other respiratory tract infections.

The diagnostic test had emergency use authorization and received approval for marketing through the FDA's "de novo" pathway, a regulatory pathway for low- to moderate-risk devices of a new type. The de novo request was based on additional data showing validation beyond what is needed for emergency use authorization.

The RP2.1 test is the first SARS-CoV-2 diagnostic test allowed to be marketed beyond the public health emergency, according to FDA's news release.

FDA approves marketing of BioFire COVID-19 test

Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases

Lucira Health files for bankruptcy despite receiving FDA green light

FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses

FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector

Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases

Lucira Health files for bankruptcy despite receiving FDA green light

FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses

FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector

FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care

BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test

Genetic causes identified for three rare diseases

Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease

FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis

Duke University researchers discover biomarkers may identify early pancreatic cancer risk

Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test

Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics

LumiraDx obtains FDA authorization for test to detect flu A, flu B, SARS-CoV-2

Lucira Health applies for FDA Emergency Use Authorization of over-the-counter COVID-19, flu A, flu B molecular test

Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings

CorDx receives FDA Emergency Use Authorization for COVID-19 antigen test

Roche obtains FDA authorization for monkeypox test on high-throughput MDx system

BD, CerTest launch monkeypox assay for global and U.S. markets